KLRS
Kalaris TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Operating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
+
Peers tracked
10
U.S. public peers
Grade Position
Above peers
vs peer average
KLRS vs peer average
80/100
KLRS vs. peer average (B vs. D)
Grade spread
B 3 · D 2 · F 5
Graded peers loaded
Coverage
10 graded
100% of tracked
Peer overview
KOD is the first available peer comparator.
The prior baseline identifies Kodiak as a retinal-development benchmark, not a direct valuation peer: its pivotal-stage program is more advanced than TH103. [Kodiak company release](https://ir.kodiak.com/news-releases/news-release-details/zenkuda-and-tabirafusp-ted-meet-primary-endpoints-pivotal)
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
KLRS
Kalaris Therapeutics
KOD
Kodiak Sciences
Grade
B
F
Momentum
74
100
Value
57
41
Sentiment
59
0
Setup Bias
Net —
-
Market Cap
-
-
Posture
Constructive
Defensive
Grade position vs KOD
KLRS / KOD
Grade Position
Above peers
KLRS vs. peer average (B vs. D)
80/100
Momentum
74
KODValue
57
KLRSSentiment
59
KLRSRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs KLRS
KOD is the first peer returned for this comparison set.